Canadian IBD Today,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 9, 2024
Sphingosine-1-phosphate
receptor
(S1PR)
modulators
are
novel
oral
small-molecule
therapies
that
offer
a
unique
profile
compared
to
other
advanced
in
the
treatment
of
ulcerative
colitis
(UC),
including
administration,
linear
pharmacokinetic
profiles,
reduced
immunogenicity,
and
lower
costs
associated
with
manufacturing.
The
activation
S1P
G-protein
coupled
receptors
plays
an
inflammatory
role
UC
by
promoting
lymphocyte
egress
from
lymphoid
organs
into
circulation
colonic
mucosa.
S1PR
lead
internalization
degradation
these
receptors,
thereby
reducing
inflammation.
Ozanimod
was
first
modulator
approved
for
treating
moderately-to-severely
active
is
also
multiple
sclerosis.
More
recently,
second
agent,
etrasimod,
UC.
Etrasimod
acts
on
different
subtypes
avoid
off
target
vascular
cardiac
effects,
has
no
up-titration
regimen
during
initiation,
shorter
half-life
less
propensity
drug
interactions.
This
review
summarizes
clinical
trial
real-world
data
provides
guidance
uses
modulators.
World Journal of Gastroenterology,
Год журнала:
2024,
Номер
30(35), С. 3942 - 3953
Опубликована: Сен. 12, 2024
Recent
advancements
in
the
treatment
landscape
of
ulcerative
colitis
(UC)
have
ushered
a
new
era
possibilities,
particularly
with
introduction
Janus
kinase
(JAK)-signal
transducer
and
activator
transcription
inhibitors.
These
novel
agents
offer
paradigm
shift
UC
management
by
targeting
key
signaling
pathways
involved
inflammatory
processes.
With
approved
JAK
inhibitors
(JAKis),
such
as
tofacitinib,
filgotinib,
upadacitinib,
clinicians
now
powerful
tools
to
modulate
immune
responses
gene
expression,
potentially
revolutionizing
algorithm
for
UC.
Clinical
trials
demonstrated
efficacy
JAKis
inducing
maintaining
remission,
presenting
viable
options
patients
who
failed
conventional
therapies.
Real-world
data
support
use
not
only
first-line
treatments
but
also
subsequent
lines
therapy,
aggressive
disease
phenotypes
or
refractory
biologic
agents.
The
rapid
onset
action
potency
broadened
possibilities
strategies
UC,
offering
timely
relief
active
facilitating
personalized
approaches.
Despite
safety
concerns,
including
cardiovascular
risks
infections,
ongoing
research
post-marketing
surveillance
will
continue
refine
our
understanding
risk-benefit
profile
management.
Canadian IBD Today,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 9, 2024
Sphingosine-1-phosphate
receptor
(S1PR)
modulators
are
novel
oral
small-molecule
therapies
that
offer
a
unique
profile
compared
to
other
advanced
in
the
treatment
of
ulcerative
colitis
(UC),
including
administration,
linear
pharmacokinetic
profiles,
reduced
immunogenicity,
and
lower
costs
associated
with
manufacturing.
The
activation
S1P
G-protein
coupled
receptors
plays
an
inflammatory
role
UC
by
promoting
lymphocyte
egress
from
lymphoid
organs
into
circulation
colonic
mucosa.
S1PR
lead
internalization
degradation
these
receptors,
thereby
reducing
inflammation.
Ozanimod
was
first
modulator
approved
for
treating
moderately-to-severely
active
is
also
multiple
sclerosis.
More
recently,
second
agent,
etrasimod,
UC.
Etrasimod
acts
on
different
subtypes
avoid
off
target
vascular
cardiac
effects,
has
no
up-titration
regimen
during
initiation,
shorter
half-life
less
propensity
drug
interactions.
This
review
summarizes
clinical
trial
real-world
data
provides
guidance
uses
modulators.
